For the quarter ending 2026-03-31, ACAD has $1,605,230K in assets. $357,164K in debts. $282,212K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 282,212 | 177,695 | 257,996 | 253,637 |
| Investment securities, available-for-sale | 569,246 | 641,991 | 589,023 | 508,359 |
| Accounts receivable, net | 135,350 | 121,457 | 115,850 | 107,505 |
| Interest and other receivables | 13,034 | 26,774 | 23,588 | 12,181 |
| Inventory | 31,574 | 34,670 | 29,097 | 26,124 |
| Prepaid expenses | 64,600 | 59,526 | 60,868 | 52,747 |
| Total current assets | 1,096,016 | 1,062,113 | 1,076,422 | 960,553 |
| Property and equipment, gross | - | 16,995 | - | - |
| Accumulated depreciation | - | 9,484 | - | - |
| Property and equipment, net | 14,652 | 7,511 | 3,708 | 3,547 |
| Operating lease right-of-use assets | 46,274 | 47,354 | 49,673 | 50,991 |
| Intangible assets, net | 106,171 | 108,893 | 111,615 | 114,338 |
| Restricted cash | 7,846 | 7,845 | 9,471 | 9,471 |
| Long-term inventory | 80,719 | 76,704 | 76,888 | 84,402 |
| Deferred tax assets | 249,624 | 249,879 | - | - |
| Other assets | 3,928 | 3,896 | 2,994 | 2,253 |
| Total assets | 1,605,230 | 1,564,195 | 1,330,771 | 1,225,555 |
| Accounts payable | 12,246 | 10,903 | 21,747 | 20,097 |
| Accrued sales allowances | 160,804 | - | - | - |
| Accrued consulting and professional fees | 43,448 | - | - | - |
| Employee-related liabilities, current, total | 31,429 | - | - | - |
| Accrued research and development services | 19,284 | - | - | - |
| Operating lease, liability, current | 11,791 | - | - | - |
| Accrued royalties | 10,399 | - | - | - |
| Other | 16,123 | - | - | - |
| Accrued liabilities | 293,278 | 266,211 | 334,837 | 309,927 |
| Total current liabilities | 305,524 | 277,114 | 356,584 | 330,024 |
| Operating lease liabilities | 39,003 | 40,554 | 43,026 | 44,601 |
| Other long-term liabilities | 12,637 | 19,137 | 13,889 | 28,548 |
| Total liabilities | 357,164 | 336,805 | 413,499 | 403,173 |
| Common stock, 0.0001 par value 225,000,000 shares authorized at march 31, 2026 and december 31, 2025 171,086,205 shares and 170,309,376 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 16 | 16 | 16 | 16 |
| Additional paid-in capital | 3,058,362 | 3,039,315 | 3,003,221 | 2,980,693 |
| Accumulated deficit | -1,809,749 | -1,813,386 | -2,086,954 | -2,158,733 |
| Accumulated other comprehensive (loss) income | -563 | 1,445 | 989 | 406 |
| Total stockholders equity | 1,248,066 | 1,227,390 | 917,272 | 822,382 |
| Total liabilities and stockholders equity | 1,605,230 | 1,564,195 | 1,330,771 | 1,225,555 |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)